Shattuck Labs STTK
Shattuck Labs FY 2022: revenue $652K, down 98%; diluted EPS −$2.41
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001680367-23-000019
- Document
- 10-K
- Exhibit 10.25
- Material contract
Key figures from this report
These are the numbers Shattuck Labs reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$652K−98% from $30.0M in FY 202110-K income statement, on EDGAR
- Net income−$101.9MAgainst −$45.0M in FY 202110-K income statement, on EDGAR
- Diluted EPS−$2.41Against −$1.07 in FY 202110-K income statement, on EDGAR
- Cash and cash equivalents$47.4M−49% from $92.3M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$94.5MAgainst −$57.1M in FY 202110-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Marimed MRMD public float $23M, Jun 30, 2025
- vTv Therapeutics VTVT public float $22M, Jun 30, 2025
- Ovid Therapeutics OVID public float $22M, Jun 30, 2025
- Lisata Therapeutics LSTA public float $24M, Jun 30, 2025
- Aptose Biosciences APTOF public float $22M, Jun 28, 2025
